生物衰老预测帕金森病患者的死亡率:来自英国生物银行的证据
Qing-Qing Duan1, Wei-Ming Su1, Kang-Fu Yin1
1Department of Neurology and Institute of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
NPJ Parkinson's disease
|January 21, 2026
概括
通过表型年龄 (PhenoAge) 测量的加速生物衰老,显著影响了帕金森氏症.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 生物统计学 生物统计学
背景情况:
- 加快的生物衰老是与年龄有关的疾病的危险因素.
- 生物衰老对帕金森病 (PD) 死亡率的预后作用尚未得到充分证实.
研究的目的:
- 研究帕金森病患者的生物衰老和死亡率之间的关联.
- 开发一种基于生物衰老标志物的PD患者生存的预测模型.
主要方法:
- 利用了来自569名PD患者的英国生物库数据.
- 使用考克斯回归评估死亡率的预后因素.
- 开发了一种包含表型年龄 (PhenoAge) 的名图,用于生存预测.
主要成果:
- 表型年龄 (PhenoAge) 和表型年龄加速 (PhenoAgeAccel) 与PD患者的存活率有关.
- 患PD死亡率的独立风险因素包括年龄,男性性别,吸烟,体重不足,抑郁情绪,LDL和遗传易感性.
- 基于PhenoAge的诺米图显示了对PD死亡率的强大预测性能.
结论:
- 现型年龄 (PhenoAge) 是帕金森病死亡率的关键预测因素.
- 识别加速生物衰老的个体可以促进有针对性的干预.
- 这项研究强调了生物衰老对PD预后的重要性.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...


